Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "platform"

1978 News Found

Agilent announces new ProteoAnalyzer system
News | January 17, 2024

Agilent announces new ProteoAnalyzer system

Automated parallel capillary electrophoresis system simplifies protein analysis


Apollo Hospital Seshadripuram partners with LifeSigns
Digitisation | January 16, 2024

Apollo Hospital Seshadripuram partners with LifeSigns

Inducts advanced AI-Powered 24x7 remote patient monitoring system


Tata Consumer Products to acquire Organic India
News | January 13, 2024

Tata Consumer Products to acquire Organic India

A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories


BioAsia 2024 to focus on data and AI for life sciences
News | January 11, 2024

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


Deloitte expands Quartz AI suite with Atlas AI for drug discovery
Digitisation | January 11, 2024

Deloitte expands Quartz AI suite with Atlas AI for drug discovery

Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design


Tata 1mg and Vitonnix UK get into an exclusive partnership in India
News | January 10, 2024

Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays


Merck to acquire Harpoon Therapeutics for US$ 680 million
News | January 10, 2024

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors


Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases
Clinical Trials | January 07, 2024

Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases

Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens


Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
News | January 07, 2024

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.